Navigation Links
Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
Date:5/24/2012

alternating electric fields.  The therapy is delivered via non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor.  TTFields therapy is frequency-tuned to target cancer cells and avoid harming normal cells. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.

About the NovoTTF-100A System

The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient.  The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.  The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.  In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy.  The most commonly reported side effect from NovoTTF-100A treatment was a mild-to-moderate rash beneath the transducer arrays. The NovoTTF-100A has received marketing approval in the U.S. and is a CE Marked device that is cleared for sale in Europe.

The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy.  The device is intended to be used as mono
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Weightlessness weighs heavy on genes a flys perspective
2. LCA-Vision to Present at the Noble Financial Eighth Annual Equity Conference
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
5. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
6. Hormone-free hCG Zero Capsules™ Boost Metabolism to Enhance Weight Loss Without Starvation
7. Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics
8. Life Technologies Employees Give Back to Their Communities During Eighth Annual Global Volunteer Day
9. A paperweight for platinum
10. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
11. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark ... of treating lung, brain, pancreatic, breast and colon cancers ... overexpression (also called EGFR or c-ErbB-1). The patent ... / S-Phase cytotoxic protocols achieve only a fraction of ...
... HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, March ... diagnostics,today announced that the Company is scheduled to ... Biotech Industry" Conference on Thursday,April 2, 2009. Presented ... has built a reputation as a major biotech ...
... SUNNYVALE, Calif. March 24 Cepheid (Nasdaq: ... revolutionize the speed of diagnosis of Mycobacterium tuberculosis ... for the disease.The new test technology, developed in partnership ... University of Medicine and Dentistry of New Jersey ...
Cached Biology Technology:Patent for Making Combination Chemotherapy Work Better 2Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 2Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 3Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 4Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 5Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB) 6
(Date:10/22/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... for its third quarter ended September 30, 2014. ... an increase of 40% compared to $4.3 million in the ... of 2014 was $4.1 million compared to $1.0 million in ... current three month period was primarily due to: i) a ...
(Date:10/18/2014)... a group of 2,000 patients referred for evaluation ... potential molecular diagnosis for 25 percent, including detection ... new mutations contributing to disease, according to a ... is being released to coincide with the American ... sequencing analyzes the exons or coding regions of ...
(Date:10/17/2014)... . Why do ... to reproduce? And why are there two sexes anyway? These ... of the research journal Molecular Human Reproduction published ... Bielefeld University Bielefeld has compiled this special issue on sperm ... to copulate with several males in quick succession – chimpanzees ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
... recently discovered compound from the aminopyridine class not only has ... all strains of malaria, but might also be able to ... to a research collaboration involving the Medicines for Malaria Venture ... Centre (H3-D) at the University of Cape Town, South Africa. ...
... cells perform an array of essential functions, including cell ... and out of cells. They are critical targets for ... as disease biomarkers early warning beacons announcing the ... study of the binding properties of membrane proteins is ...
... Disruptions to the circadian rhythm can affect the growth of ... diabetes, obesity, and cancer, according to a new study from ... is regulated by a "clock" that reacts to both incoming ... in the scientific journal Cell Reports , it is ...
Cached Biology News:African research identifies strong candidate for possible single-dose malaria cure 2African research identifies strong candidate for possible single-dose malaria cure 3A new look at proteins in living cells 2A new look at proteins in living cells 3A new look at proteins in living cells 4
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: